through inhibition of CETP will be beneficial for the treatment of atherosclerosis remains open and should be evaluated with a CETP inhibitor that does not carry inherent cardiovascular liabilities. Conflict of interest All authors of this manuscript are currently or previously (HV) were employees of Merck and Co., Whitehouse Station, NJ, USA. References Assmann G, Schulte H (1992). Relation of high density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 70: 733–737. Barter PJ, Brewer Jr HB, Chapman MJ, Hennekens CH, Rader DJ, Tall AR (2003). Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23: 160–167. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M et al. (2007). Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357: 2109–2122. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW et al. (2004). Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350: 1505–1515. Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus- Aryitey G et al. (2004). Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 24: 490–497. Connell JMC, Davies E (2005). The new biology of aldosterone. J Endocrinol 186: 1–20. Davidson MH, McKenney JM, Shear CL, Revkin JH (2006). Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipopro- tein cholesterol levels. J Am Coll Cardiol 48: 1774–1781. Eveland SS, Milot DP, Guo Q, Chen Y, Hyland SA, Peterson LB et al. (2007). A high-precision fluorogenic cholesteryl ester transfer protein assay compatible with animal serum and 3456-well assay technology. Anal Biochem 368: 239–249. Fredlund P, Saltman S, Catt KJ (1975). Aldosterone production by isolated adrenal glomerulosa cells: stimulation by physiological concentrations of angiotensin II. Endocrinology 97: 1577–1586. Gillespie JS, MacLaren A, Pollack D (1970). A method of stimulating different segments of the autonomic outflow from the spinal column to various organs in the pithed cat and rat. Br J Pharmacol 40: 257–267. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD et al. (1989). High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 79: 8–15. Grooth J, Kuivenhoven J, Stalenhoef A, de Graaf J, Zwinderman A, Posma J et al. (2002). Efficacy and safety of a novel cholesteryl ester transfer inhibitor, JTT-705, in humans. Circulation 105: 2159–2165. LaRosa JC, He J, Vupputuri S (1999). Effect of statins on risk of coronary disease; a meta-analysis of randomized controlled trials. JAMA 282: 2340–2346. Aldosterone and pressor responses to torcetrapib MJ Forrest et al 1473 Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339: 1349–1357. Keidar S, Hayek T, Kaplan M, Pavlotzky E, Hamoud S, Coleman R et al. (2003). Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 41: 955–963. Maron DJ, Fazio S, Linton MF (2000). Current perspective on statins. Circulation 101: 207–213. McKenney JM, Davidson MH, Shear CL, Revkin JH (2006). Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipopro- tein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol 48: 1782–1790. Nishikibe M, Ohta H, Okada M, Ishikawa K, Hayama T, Fukuroda T et al. (1999). Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antago- nist. J Pharmacol Exp Ther 289: 1262–1270. Nissen SE, Tardif J-C, Nicholls SJ, Revkin JH, Shear CL, Duggan WT et al. (2007). Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356: 1304–1316. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H (2000). A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406: 203–207. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. (2003). Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309–1321. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341: 709–717. Rocha R, Funder JW (2002). The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci 970: 89–100. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: 1001–1009. Scandinavian Simvastatin Survival Study Group (1994). Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 344: 1383–1388. Schiffrin EL (2006). Effects of aldosterone on the vasculature. Hypertension 47: 312–318. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al., for the ASCOT Investigators (2003). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA). Lancet 361: 1149–1158. Stoccco DM, Clark BJ (1996). Regulation of the acute production of steroids in steroidogenic cells. Endocr Rev 17: 221–244. Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M, Okamoto H et al. (1998). Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem 273: 5033–5036. Ullian ME (1999). The role of corticosteroids in the regulation of vascular tone. Cardiovasc Res 41: 55–64. Vasan RS, Evans JC, Larson MG, Wilson PWF, Meigs JB, Rifai N et al. (2004). Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 351: 33–41. Supplementary Information accompanies the paper on British Journal of Pharmacology website (http://www.nature.com/bjp) BJPOpen This article is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 Licence. To view a copy of this licence, visit http://creativecommons.org/licences/by-nc-nd/3.0/ This article is available free of charge on the BJP website (http://www.brjpharmacol.org). British Journal of Pharmacology (2008) 154 1465–1473